Antisense remains on track to positive clinical trial results
Finfeed
Archived
Mar 18, 2020
The recent completion of the monitoring phase of Antisense Therapeutics Limited's (ASX: ANP) ATL1102 Phase II Duchenne Muscular Dystrophy (DMD) trial remains on track for the end of March 2020.
